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Summary
Increased glucose production (GP) is the major determinant of fasting hyperglycemia in diabetes mellitus. Previous studies
suggested that lipid metabolism within specific hypothalamic nuclei is a biochemical sensor for nutrient availability that
exerts negative feedback on GP. Here we show that central inhibition of fat oxidation leads to selective activation of
brainstem neurons within the nucleus of the solitary tract and the dorsal motor nucleus of the vagus and markedly
decreases liver gluconeogenesis, expression of gluconeogenic enzymes, and GP. These effects require central activation
of ATP-dependent potassium channels (KATP) and descending fibers within the hepatic branch of the vagus nerve. Thus,
hypothalamic lipid sensing potently modulates glucose metabolism via neural circuitry that requires the activation of KATP
and selective brainstem neurons and intact vagal input to the liver. This crosstalk between brain and liver couples central
nutrient sensing to peripheral nutrient production and its disruption may lead to hyperglycemia.Introduction
The worldwide epidemic of obesity-driven diabetes mellitus
(Moller, 2001; Kahn and Flier, 2000; Kopelman, 2000; Fried-
man, 2000) has generated a sense of urgency in the quest for
basic mechanisms coupling energy balance with glucose ho-
meostasis (Obici and Rossetti, 2003; Flier, 2001, 2004). Modu-
lation of lipid metabolism within the hypothalamus results in
dramatic changes in energy balance and glucose metabolism
(Obici et al., 2002b, 2003; Loftus et al., 2000). In this regard,
the mitochondrial oxidation of long-chain fatty acylCoAs (LC-
CoAs) requires two membrane bound carnitine-dependent
long-chain acyl-transferases, also known as carnitine palmi-
toyltransferases (CPT1 and CPT2). CPT1 is located on the outer
mitochondrial membrane, catalyzes the formation of long-chain
acylcarnitines, and is present in two isoforms known as the liver,
CPT1 liver (encoded by the CPT1-A gene), and the muscle,
CPT1-M (encoded by the CPT1-B gene) isoform. Ribozyme-
induced antagonism of CPT1 liver expression resulting in a selec-
tive decrease in CPT1 activity within the arcuate nucleus of the
hypothalamus is sufficient to markedly inhibit liver glucose output.
Similarly, the administration of a selective inhibitor of CPT1 liver
activity in the third cerebral ventricle increases the concentration
of LC-CoAs in the arcuate nucleus (but not in other hypothalamic
nuclei) and results in a marked suppression of liver glucose out-
put (Obici et al., 2003). Thus, inhibition of hypothalamic lipid oxi-
dation via either molecular or biochemical means results in cellu-
lar accumulation of LC-CoAs within the arcuate nucleus of the
hypothalamus and leads to marked inhibition of food intake and
GP (Obici et al., 2003). We postulated that this represents a
central signal of “nutrient abundance,” which in turn activates a
chain of neuronal events designed to switch fuel sources from
carbohydrates to lipids and to limit the further entry of nutrients
in the circulation.
KATP are expressed in the hypothalamus (Spanswick et al.,
1997, 2000) and can be activated by LC-CoAs in isolated cells
(Larsson et al., 1996; Gribble et al., 1998). Of interest, leptinCELL METABOLISM : JANUARY 2005 · VOL. 1 · COPYRIGHT © 2005 ELand insulin can also activate KATP in selective hypothalamic
neurons (Spanswick et al., 1997, 2000), and the rapid effects
of insulin on liver glucose homeostasis require central activa-
tion of KATP (Obici et al., 2002c). Leptin modulation of the im-
pact of meal-related signals on food intake is related to
increased activation of brainstem nuclei (Grill et al., 2002).
Here, we postulate that central inhibition of fat oxidation modu-
lates liver glucose homeostasis via KATP-dependent changes in
neuronal activity leading to increased vagal outflow to the liver.
Results
Central inhibition of fat oxidation results in KATP-
dependent suppression of GP
Sulfonylureas (KATP blockers) are potent inhibitors of KATP, and
they block the activation of hypothalamic KATP by insulin and
leptin (Spanswick et al., 1997, 2000). We combined ICV infu-
sions with systemic pancreatic-insulin clamp studies (Figure
1A). Paired groups of rats received ICV infusions of either the
CPT1 inhibitor ST1326 or of the inactive stereo-isomer ST1340
(Kindly provided by Dr. Roberto Conti, Sigma-Tau Italy; Supple-
mental Figure S1). The baseline characteristics of the experi-
mental rats were similar in each group compared with the ap-
propriate control (Supplemental Table S1A). In the presence of
near basal circulating insulin levels, glucose infusion was re-
quired to prevent hypoglycemia following central inhibition of
CPT1 activity with ST1326. ICV infusion of the KATP-blocker
glybenclamide alone did not modify the rate of glucose infusion
(GIR) compared with ICV vehicle (Figure 1C). Importantly,
central inhibition of fat oxidation did not affect GIR when the
KATP blocker was coinfused. We next assessed glucose kinet-
ics by tracer dilution methodology (Obici et al., 2001, 2002b;
Liu et al., 1998) in order to establish whether the KATP-depen-
dent increase in GIR induced by central antagonists of CPT1
activity is due to stimulation of glucose uptake or to suppres-
sion of GP. The rate of glucose uptake was not significantly
affected by ICV treatments (Figure 1D). Conversely, in the pres-SEVIER INC. DOI:10.1016/j.cmet.2004.11.001 53
A R T I C L EFigure 1. Inhibition of hypothalamic CPT1 improved hepatic insulin action via KATP channels
Diagram of the experimental procedures (A and B, see Experimental procedures). ICV KATP blocker blocks the improvement in insulin sensitivity due to central inhibition
of fat oxidation. Glucose infusion rate (C) and glucose uptake (D) are shown. ICV KATP blocker prevents the suppressive effect of central inhibition of fat oxidation on
glucose production. Before the start of the pancreatic clamp, the rates of GP were similar in all experimental groups. During the pancreatic clamp, ICV ST1326
decreased GP as compared to ICV ST1340. This effect was blocked by coinfusion of KATP blocker while KATP blocker and ST1340 did not affect GP (E and F).ence of basal and equal insulin levels (w20 U/ml), ICV
ST1326 markedly and significantly decreased GP (Figures 1E
and 1F) (by 47% ± 5%). The decrease in GP was negated by
the ICV coinfusion of KATP blocker and completely accounted
for the effect of ST1326 on whole body glucose metabolism.
On the basis of these results, we conclude that central inhi-
bition of fat oxidation results in KATP-dependent suppression
of GP.
GP represents the net contribution of glucosyl units derived
from gluconeogenesis and glycogenolysis. However, a portion
of glucose entering the liver via phosphorylation of extracellular
glucose is also a substrate for dephosphorylation via glucose-
6-phosphatase (G6Pase). This futile cycle between glucoki-
nase and G6Pase is commonly named glucose cycling and ac-
counts for the difference between the overall flux through
G6Pase and GP.
In order to further delineate the mechanisms by which
central inhibition of fat oxidation modulates glucose homeosta-
sis, we estimated the in vivo flux through G6Pase and the rela-
tive contribution of glucose cycling, gluconeogenesis, and gly-
cogenolysis to glucose output. Supplemental Table S2 displays54the specific activities of intrahepatic [14C]-Phosphoenolpy-
ruvate (PEP), [3H]- and [14C]-UDPglucose, and plasma [3H]-glu-
cose used to calculate the contribution of PEP and plasma glu-
cose to the hepatic G6P (glucose-6-phosphate) pool. As
shown in Figure 2A, ICV ST1326 markedly decreased the flux
through G6Pase in parallel to its effects on GP (Figures 1E and
1F). In keeping with the marked decrease in glucose output the
rates of glucose cycling were also markedly decreased by the
ICV infusion of ST1326 (Figure 2B). The decrease in GP was
mostly accounted for by a marked inhibition of gluconeogene-
sis (Figure 2E) while the rate of glycogenolysis was only mod-
estly decreased (Figure 2D). Importantly, in the presence of ICV
sulfonylurea, central inhibition of fat oxidation did not modify
hepatic glucose fluxes. Based on the above in vivo results, we
next assessed the effect of central inhibition of fat oxidation on
G6Pase and PEPCK gene expression in liver harvested at the
completion of the infusions. Real-time PCR analyses revealed
that ICV ST1326 resulted in marked KATP-dependent
decreases in liver G6Pase and PEPCK mRNA levels (Figures
2C and 2F). Thus, the marked decreases in the in vivo flux
through G6Pase and gluconeogenesis with ICV ST1326 mayCELL METABOLISM : JANUARY 2005
Mechanisms for hypothalamic lipid sensingFigure 2. ICV KATP-blocker abolishes the effect of
inhibition of central fat oxidation on the expression
of key hepatic gluconeogenic genes
Central administration of KATP blocker negates the
inhibitory effect of ICV ST1326 on flux through Glu-
cose-6-phosphatase (G6Pase, A) and glucose cy-
cling (B). The effect of ST1326 on GP was entirely
accounted for by a potent suppression of gluconeo-
genesis (E) while glycogenolysis (D) was only mod-
estly decreased. Coinfusion of ST1326 and KATP
blocker negates the suppressive effect of central fat
oxidation on gluconeogenesis. G6Pase (C) and
phosphoenolpyruvate carboxykinase (PEPCK, F)
gene expressions were strongly inhibited by
ST1326, and ICV infusion of KATP blocker com-
pletely prevents this effect. *p < 0.05 versus vehicle
controls, ^p < 0.05 versus baseline period.be largely ascribed to decreased hepatic expression of the ca-
talytic subunit of G6Pase and PEPCK. The latter effects were
completely prevented by ICV infusion of a KATP blocker (Fig-
ures 2C and 2F).
Central inhibition of CPT1 activity leads to KATP-
dependent activation of selective brainstem neurons
We postulate that the activation of a KATP-dependent descend-
ing neuronal pathway conveys neural input to the liver by mod-
ulating neuronal activity in the autonomic centers of the hind-
brain. Since c-Fos expression is a well-established marker for
neuronal activation (Mistry et al., 1994; Emond et al., 2001b),
we next investigated whether central inhibition of CPT1 activity
with ST1326 leads to specific neuronal activation within the
NTS and DMX areas of the brainstem. ICV infusion of the CPT1
inhibitor elicited c-Fos expression in selective cells of the DMX
and NTS (Figure 3A), whereas control ICV infusion of its stereo-
isomer did not elicit neuronal activation (Figure 3B). These
c-Fos-expressing regions correspond to brainstem representa-
tions of upper gastrointestinal sites, including the duodenum
and liver. Importantly, the ICV infusion of a KATP blocker com-
pletely prevented the increase in c-Fos expression (Figure 3C)
while central inhibition of KATP per se did not elicit c-fos ex-
pression in brainstem nuclei (Supplemental Figure S3). Quanti-
fication of the immunohistochemistry staining reveals that sev-
eral neurons within the NTS and in the DMX displayed c-Fos
expression 2 hr after central inhibition of CPT1 activity (Figure
3, bottom). Thus, the effects of central inhibition of fat oxidation
on brainstem c-Fos expression as well as on hepatic gene ex-
pression and metabolic fluxes require activation of KATP.
Furthermore, the modulatory action on NTS neurons is likely to
contribute to the anorectic action of CPT1 inhibitors (Obici et
al., 2003).
Vagal outflow to the liver is required for the effect
of central lipid signaling on GP
Since autonomic neural input to the liver can modulate liver
metabolism (Xue et al., 2000; Matsuhisa et al., 2000; Moore etCELL METABOLISM : JANUARY 2005al., 1993), we next asked whether central inhibition of fat oxida-
tion leading to selective neuronal activation in the DMX and
NTS decreases GP and the expression of G6Pase and PEPCK
via increased vagal input to the liver. To this end, the ICV infu-
sions of ST1326 and ST1340 were repeated following selective
hepatic branch vagotomy (HV) or sham operation (SHAM) (Fig-
ure 4A). Paired groups of rats received an infusion of either the
CPT1 inhibitor or of the inactive stereo-isomer (Figure 4B). In
the presence of approximately basal circulating insulin levels,
glucose infusion was required to prevent hypoglycemia follow-
ing central inhibition of CPT1 activity with ST1326 in the SHAM
but not in the HV rats (Figure 4C). We next assessed glucose
kinetics in order to establish whether the vagus-dependent
increase in GIR induced by central antagonists of CPT1 was
due to stimulation of glucose uptake or to suppression of GP.
The rate of glucose uptake was not significantly affected by
ICV treatments in either SHAM or HV rats (Figure 4D). Con-
versely, in the presence of basal and equal insulin levels, ICV
ST1326 markedly and significantly decreased GP (by 48% ±
3%) in SHAM but not in HV rats (Figures 4E and 4F). On the
basis of these results, we conclude that the central inhibition
of fat oxidation results in vagus-dependent suppression of GP.
We next estimated the in vivo flux through G6Pase and the
relative contribution of glucose cycling, gluconeogenesis, and
glycogenolysis to glucose output. As shown in Figure 5A, ICV
ST1326 markedly decreased the flux through G6Pase in the
SHAM rats in parallel to its effects on GP (Figures 4E and 4F).
Consistent with the marked changes in glucose output, the
rates of glucose cycling were also markedly decreased by the
ICV infusion of ST1326 (Figure 5B). The decrease in GP was
largely accounted for by a marked inhibition of gluconeogene-
sis (Figure 5E). Importantly, in rats with hepatic branch vagot-
omy, central inhibition of fat oxidation failed to affect hepatic
glucose fluxes. Based on the above in vivo results, we exam-
ined the effect of central inhibition of fat oxidation on G6Pase
and PEPCK gene expression in liver harvested at the comple-55
A R T I C L EFigure 3. ICV administration of the CPT1 inhibitor
ST1326 promotes selective expression of c-fos pro-
tein in upper gastrointestinal sensory and motor re-
gions of the caudal hindbrain
A) ST 1326 activated c-fos expression in the nu-
cleus of the solitary tract (NTS), dorsal motor vagal
nucleus (DMX), and the area postrema (AP) at me-
dial, rostral, and extreme rostral levels of the caudal
brainstem. These c-fos-expressing regions corre-
spond to brainstem representations of upper gas-
trointestinal sites, including the duodenum and liver.
B) In contrast, the inactive enantiomer ST1340 elic-
ited no c-fos expression.
C) ICV infusion of a KATP blocker completely pre-
vented the ST1326-induced expression of c-fos at
each level of the brainstem.tion of the infusions (Figures 5C and 5F). Real-time PCR analy-
ses revealed that ICV ST1326 resulted in marked vagus-depen-
dent decreases in liver G6Pase and PEPCK mRNA levels.
Thus, the marked decreases in the in vivo flux through G6Pase
and PEP-gluconeogenesis following central inhibition of fat ox-
idation may be largely ascribed to decreased hepatic expres-
sion of the catalytic subunit of G6Pase and PEPCK. The latter
effects were completely negated by hepatic branch vagotomy
(Figures 5C and 5F).
Afferent vagal input to the brainstem is not required
for the effect of central lipid signaling on GP
The hepatic branch of the vagus nerve is comprised of efferent
and afferent fibers. To establish whether afferent vagal fibers
are required for the effects of ST1326 on GP, a separate group
of rats underwent selective vagal deafferentation. These ani-
mals have intact descending efferent fibers to the liver but their
afferent vagus branch is resected at the site of entry in the56brainstem (Figure 6A). The ICV infusion of ST1326 was equally
effective in stimulating GIR and in suppressing GP in the pres-
ence or absence of vagal deafferentation (Figure 6B).
Discussion
Precise regulation of liver glucose output is necessary to en-
sure adequate availability of energy sources for the brain (Ev-
ans and Sherwin, 2002). Here we show that a novel pathway
for brain-liver crosstalk couples lipid sensing in the hypothala-
mus to liver glucose homeostasis. Our data provide strong
support for three basic observations: (1) decreasing hypothala-
mic lipid oxidation in the presence of basal circulating insulin
levels inhibits glucose production via activation of central KATP;
(2) decreasing hypothalamic lipid oxidation also leads to a
KATP-dependent activation of selective neurons within auto-
nomic centers in the brainstem; and (3) the effects of central
modulation of lipid oxidation on liver glucose fluxes and gene
expression requires vagal outflow through the hepatic branchCELL METABOLISM : JANUARY 2005
Mechanisms for hypothalamic lipid sensingFigure 4. Inhibition of hypothalamic CPT1 improved hepatic insulin action via hepatic vagus nerve
Experimental procedures (A and B see Experimental procedures). Hepatic vagotomy (HV) blocks the improvement in insulin sensitivity due to central inhibition of fat
oxidation. Glucose infusion rate (C) and glucose uptake (D) are shown. HV prevents the suppressive effect of central inhibition of fat oxidation on glucose production
(GP). Before the start of the pancreatic clamp, the rates of GP were similar in all experimental groups. During the pancreatic clamp, ICV ST1326 decreased GP as
compared to ICV ST1340. This effect was blocked by HV while sham operation (SHAM) and ST1340 did not affect GP (E and F).of the vagus. Pharmacological blockade of hypothalamic fat
oxidation sufficient to alter hepatic glucose production also
stimulated c-Fos expression in neurons of the nucleus of the
solitary tract and the dorsal motor vagal nucleus, two brain-
stem regions that mediate sensory and motor aspects of gas-
trointestinal innervation, respectively. These immunocytochemical
findings suggest potential roles for hypothalamic lipid sensing
in the modulation of hepatic vagal sensory processing and he-
patic vagal efferent activity. Since the hepatic branch of the
vagus was required for its metabolic actions on the liver, our
data also demonstrate that hypothalamic lipid metabolism
modulates hepatic glucose production via the hepatic vagus
nerve. Based on the immunocytochemical and vagotomy re-
sults, we propose that this modulation occurs via vagal effer-
ents that supply the liver via the hepatic vagus. Inhibition of
central fat oxidation has also been shown to reduce food in-
take, and the stimulation of c-Fos in the sensory NTS may be
related to its inhibitory action on feeding behavior.
The hepatic branch provides the primary vagal innervation
of the rat liver, but also supplements vagal innervation of the
duodenum (Berthoud et al., 1991) and perhaps of the pancreas
(Berthoud et al., 1990). Although it may be argued that changesCELL METABOLISM : JANUARY 2005in pancreatic islet function may contribute to the potent effects
of central inhibition of fat oxidation on hepatic glucose metabo-
lism, this is unlikely because (1) baseline glucagon and insulin
levels were not affected by hepatic branch vagotomy and (2)
measurements of hepatic glucose fluxes were performed in the
presence of pancreatic clamp conditions to prevent potential
alterations in glucagon and insulin levels. Our data do not sup-
port a significant role of hypothalamic KATP or hepatic vagus in
the modulation of normal postabsorptive glucose homeostasis
since in the presence of basal insulin concentrations neither
central inhibition of KATP or hepatic vagotomy per se altered
glucose homeostasis. Conversely, when hypothalamic lipid ox-
idation was inhibited, blocking the activation of central KATP or
hepatic branch vagotomy markedly affected the regulation of
glucose production (Figure 7). Similarly, when insulin levels are
increased via a systemic insulin infusion, the activation of
central KATP is required for the effect of insulin on glucose pro-
duction (Obici et al., 2002c). Thus, this brain-liver circuit ap-
pears to be required to restrain hepatic glucose production in
the presence of increased hypothalamic levels of insulin or
LCFA. In this regard, it is noteworthy that short-term hyperpha-
gia rapidly induces hepatic insulin resistance in rats. Further-57
A R T I C L EFigure 5. Hepatic vagotomy abolishes the effect of
inhibition of central fat oxidation on the expression
of key hepatic gluconeogenic genes
HV negates the inhibitory effect of ICV ST1326 on
Glucose-6-phosphatase flux (G6Pase, A) and glu-
cose cycling (B). The effect of ST1326 on GP is en-
tirely accounted for by a potent suppression of glu-
coneogenesis (E) while the rate of glycogenolysis
(D) was only modestly decreased. HV negates the
suppressive effect of central fat oxidation on gluco-
neogenesis. Glucose-6-phosphatase (G6Pase, C)
and phosphoenolpyruvate carboxykinase (PEPCK,
F) gene expressions are strongly inhibited by
ST1326, and HV completely prevents this effect.
*p < 0.05 versus vehicle controls, ^p < 0.05 versus
baseline period.the early stages in the development of diet-induced obesity. It
Figure 6. Afferent vagal input to the brainstem is not required for the effect of
central lipid signaling on GP
The hepatic branch of the vagus nerve is comprised of efferent and afferent
fibers. To establish whether afferent vagal fibers within the hepatic branch are
required for the effects of ICV ST1326 on GP, a separate group of rats underwent
selective vagal deafferentation. In this surgical procedure, the left vagal afferent
rootlet is resected where it attaches to the brainstem. Thus, these rats have intact
descending efferent fibers to the liver but they lack right abdominal afferent vagal
input to the CNS. The ICV infusion of ST1326 did not alter the rate of glucose
disappearance (Rd) and it was equally effective in stimulating GIR and in sup-
pressing GP in rats receiving vagal deafferentiation or sham operation.more, over-fed rats also rapidly develop severe resistance to
the metabolic and feeding effects of both leptin and oleic acid
(Wang et al., 2001; Morgan et al., 2004). Importantly, preliminary
evidence suggests that short-term hyperphagia did not alter the
suppressive effect of ICV ST1326 on GP (data not shown). Thus,
this brain-liver circuit appears to be functionally intact during58remains to be demonstrated whether and how changes in the
concentration of circulating lipids and perhaps of other nutri-
ents can directly signal energy status to the hypothalamus.
This may require induction of selective loss of function within
this brain-liver neurocircuit in the presence of physiological
changes in plasma lipid levels. Under physiological conditions,
cellular fat oxidation is regulated by the availability of malonyl-
CoA, a potent inhibitor of CPT1 activity. Since malonyl-CoA
is largely derived from the glycolysis of glucosyl-derived units
(McGarry et al., 1977; Ruderman et al., 1997), this biochemical
pathway is ideally positioned to monitor central carbohydrate
and lipid availability in order to couple nutrient sensing in the
hypothalamus to nutrient production by the liver. This neurocir-
cuitry linking hypothalamic centers with autonomic innervation
of the liver adds a new dimension to the emerging role of the
vagus nerve as a transducer of peripheral energy signals into
multiple regulatory functions such as modulation of meal size
(Emond et al., 2001a; Moran et al., 2001; Schwartz et al., 2000),
cardiovascular function (Grundy, 2003), and inflammatory re-
sponses (Tracey, 2002). It is reasonable to postulate that selec-
tive modulation of vagus nerve activity may one day provide
therapeutic advantages in diabetes and the metabolic syn-
drome (Kopelman, 2000; Moller, 2001; Zimmet et al., 2001;
Grundy, 2003).
Experimental procedures
Animal preparation for the in vivo experiments
We studied seventy-eight 10-week-old male Sprague-Dawley rats (Charles
River Breeding Laboratories, Wilmington, Massachusetts). Rats were
housed in individual cages and subjected to a standard light-dark cycle.
Three weeks prior to the in vivo studies, we implanted chronic catheter in
the third cerebral ventricle by stereotaxic surgery (Obici et al., 2001, 2002c;
Liu et al., 1998). One week before the pancreatic-insulin clamp protocols,
rats received additional catheters in the right internal jugular and left carotid
artery (Figures 1A and 3A; Liu et al., 1998; Obici et al., 2001, 2002c).CELL METABOLISM : JANUARY 2005
Mechanisms for hypothalamic lipid sensingFigure 7. Scheme of the neural and metabolic
mechanisms by which central inhibition of fat oxida-
tion decreases glucose production
Inhibition of fatty acid oxidation with CPT1 inhibitors
leads to accumulation of LCFA-CoA in the arcuate
nucleus, which in turn opens KATP channels. This
results in the activation of autonomic projections
from the hypothalamus that synapse on the dorsal
vagal complex, which includes the dorsal motor nu-
cleus of the vagus (DMX). Efferent vagal outflow to
the liver decreases glucose production, mainly by
decreasing the formation of gluconeogenic precur-
sor and by downregulating G6Pase and PEPCK ex-
pression.Selective hepatic branch vagotomy
One week before the clamp procedure a subgroup of rats were subjected
to selective hepatic vagotomy (HV) or to sham operation (SHAM) (la Fleur
et al., 2003). Briefly, a laparotomy incision is made on the ventral midline
and the abdominal muscle wall is opened with a second incision, revealing
the gastrointestinal tract in the peritoneum. The gastrohepatic ligament is
severed using fine forceps, and the stomach is gently retracted onto sterile
saline-soaked cotton gauze, revealing the descending ventral esophagus
and the ventral subdiaphragmatic vagal trunk. The hepatic branch of this
vagal trunk is then transected by microcautery in between the two sutures,
severing and cauterizing the hepatic vagus, thereby minimizing the possi-
bility of regeneration. Anatomical nerve transactions were verified in each
rat at sacrifice by microscopic observation of the absence of vagal nerve
fibers in between the two silk sutures that had been placed along the trunk
at the time of transection.
Selective vagal deafferentation
Nerve transection was performed as previously described (Schwartz et al.,
1999; Sclafani et al., 2003), according to the methods of Norgren and Smith
(1994). Briefly, the ventral muscles of the neck were exposed by a midline
skin incision, the omo- and sternohyoideus muscles were gently retracted,
revealing the base of the left skull. A hole was drilled into the base of the
skull, revealing the brainstem and overlying dura. The dura was broken,
permitting observation of left vagal afferent and efferent rootlets where they
attach to the brainstem. The afferent rootlet was then avulsed using fine
forceps completely disconnecting it from the brainstem.
ICV delivery of CPT1 inhibitors
For the pancreatic-insulin clamp studies, ST1326 [(R)-N-(tetradecylcarba-
moyl)-aminocarnitine] and ST1340 (the inactive stereo-isomer of ST1326)
[(S)-N-(tetradecylcarbamoyl)-aminocarnitine] (Sigma-Tau Department of Me-
tabolism & Endocrinology, Sigma Tau Pharmaceutical Industries, Pomezia,
Italy) (Giannessi et al., 2003) were dissolved in artificial cerebrospinal fluid
(aCSF) and infused at a rate of 50 pmol/hr. Sulfonylurea (glybenclamide)
was dissolved in 2% Dimethyl-sulfoxide (DMSO) in aCSF and infused at a
rate of 500 pmol/hr.
In vivo glucose kinetics and pancreatic-insulin clamp procedure
The infusion studies lasted a total of 360 min (Figures 1B and 2B). At t = 0
min, a primed-continuous ICV infusion of ST1326 or ST1340, with or with-CELL METABOLISM : JANUARY 2005out glybenclamide, was initiated and maintained for the 6 hr-long study (t =
360). The pancreatic-insulin clamp procedure was performed as described
(Liu et al., 1998; Obici et al., 2001, 2003).
c-Fos detection
Following 2 hr of ICV infusion of ST1326 (50 pmol/hr), ST1340 (50 pmol/hr),
with or without sulphonylurea (500 pmol/hr), brains were perfused trans-
cardially via a 16-gauge needle placed in the left ventricle and c-Fos immu-
nohistochemical staining and quantitative analysis were performed as pre-
viously described (Emond et al., 2001b).
Quantitation of gluconeogenic genes by real-time RT-PCR
Total RNA from liver was extracted using Trizol (Invitrogen). Single-stranded
cDNA synthesis and real-time PCR reactions were done as described be-
fore (Obici et al., 2002a, 2003). Glucose-6-phosphatase (G6Pase) and phos-
phoenolpyruvate carboxykinase (PEPCK) gene expressions were mea-
sured by real-time PCR. PEPCK and G6Pase mRNA primers contained the
following sequences: PEPCK, forward, 5#-GCCTCCTCAGCTGCATAATGG
TCT-3# and reverse, 5#-GAATGCTTTCTCGAAGTCCTCTTCTG-3#; G6Pase,
forward, 5#-GCGACCGTCCCCTTTGCATCTGTC-3# and reverse, 5#-CCAC
CAAACACTCCCCCTCCTCC-3#; 18s, forward, 5#-AGGGTTCGATTCCGGA
GAGG-3# and reverse, 5#-CAACTTTAATATACGCTATTGG-3#.
The copy number of each transcript was derived from a standard curve
of cloned target templates. Expression of each transcript was normalized
to copy number for 18s ribosomal protein. Rate of hepatic glucose fluxes
were determined as described (Rossetti et al., 1993). All values are pre-
sented as the means ± SEM. Comparisons among groups were made using
analysis of variance or unpaired Student’s t test as appropriate. The study
protocol was reviewed and approved by the Institutional Animal Care and
Use Committee of the Albert Einstein College of Medicine.
Supplemental data
Supplemental data associated with this article can be found in the online
version at http://www.cellmetabolism.org/cgi/content/1/1/53/DC1/.
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